Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Tofacitinib

2

XVII.b Opportunistic pulmonary/systemic infections

1
Last update : 31/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Digging into the Histology.
The New England journal of medicine 2023 Oct 05;389;1321-1326 2023 Oct 05
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Journal of Crohn's & colitis 2023 Apr 03;17;338-351 2023 Apr 03
Atypical presentation of pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation.
BMC rheumatology 2018;2;34 2018
Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Journal of drugs in dermatology : JDD 2015 Aug;14;901-2 2015 Aug
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012 Sep;12;2446-56 2012 Sep
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
The New England journal of medicine 2012 Aug 09;367;495-507 2012 Aug 09
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
The New England journal of medicine 2012 Aug 09;367;508-19 2012 Aug 09

Powered by

  • ^
  • Contact
  • Cookies
  • About